Large Outflow of Money Witnessed in Sanofi

Sanofi (SNY) traded on a positive note gaining 0.03 points or 0.07% to be valued at $40.81 per share. Intraday, the shares aggregated $3.62 million in upticks but saw an exodus of $5.39 million in downticks. The net money flow was calculated to be $(-1.78) million with the final up/down ratio coming in at 0.67. The share price has seen a change of 2.33% in value during the week. Block trade of up/down ratio of 0 was also registered with $0 million in upticks and $2.19 million in downticks. The net money flow for the block exchange was disappointing at $(-2.19) Million.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.

Shares of Sanofi rose by 2.48% in the last five trading days and 1.09% for the last 4 weeks. Sanofi is up 5.12% in the last 3-month period. Year-to-Date the stock performance stands at 1.09%. Sanofi (NYSE:SNY) rose 0.25% or 0.1 points on Wednesday and made its way into the gainers of the day. After trading began at $40.62 the stock was seen hitting $40.88 as a peak level and $40.5 as the lowest level. The stock ended up at $40.88. The daily volume was measured at 1,563,121 shares. The 52-week high of the share price is $44.5 and the 52-week low is $36.8101. The company has a market cap of $105,234 million.

Sanofi SA (ADR) Last issued its quarterly earnings results on Oct 28, 2016. The company reported $1.79 EPS for the quarter, beating the analyst consensus estimate by $ 0.25. Analyst had a consensus of $1.54. The company had revenue of $9652.00 million for the quarter, compared to analysts expectations of $9522.09 million. The companys revenue was up .6% compared to the same quarter last year.

Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Sanofi SA (ADR) was Initiated by Goldman to Neutral on Nov 7, 2016.

Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing of healthcare products. Its strategy is built around three priorities to reach its goals and ensure sustainable growth. The priorities are: increasing innovation in Research and Development, adapting Group structures to future challenges and seizing external growth opportunities. Sanofi-Aventis specializes in six therapeutic areas: thrombosis, cardiovascular, metabolic disorders, oncology, central nervous system (CNS) and internal medicine. The Company offers vaccines in five areas: pediatric combination vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. Sanofi-Aventis is headquartered in Paris, France.


Share this post

Leave a Reply